


Achaogen
Investor Relations Department
7000 Shoreline Court,
3rd Floor
South San Francisco, CA 94080
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: AKAO


Last Trade:	11.78
Trade Time:	3:54 PM ET Nov 17, 2017
Change:	-0.17  (1.423%)
Day Range	11.68 - 12.03
52-Week Range	4.67 - 27.79
Volume	652,392

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, or CRE. In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent a... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 8, 2017
[Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- Nov 6, 2017
[Achaogen to Present at the Stifel 2017 Healthcare Conference](#)
- Oct 30, 2017
[Achaogen to Host Conference Call and Webcast of Third Quarter 2017 Financial Results on November 8, 2017](#)
- Oct 27, 2017
[Achaogen Announces New Employment Inducement Grants](#)
- Oct 26, 2017
[Achaogen Submits Plazomicin New Drug Application \(NDA\) to the U.S. FDA for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 14, 2017
[Annual Report \(10-K\)](#)
- Apr 26, 2017
[Proxy Statement \(DEF 14A\)](#)
- Nov 8, 2017
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017
[Quarterly Report \(10-Q\)](#)
- May 8, 2017
[Quarterly Report \(10-Q\)](#)